New therapeutic target in primary headaches - blocking theCGRP receptor

Area of Science:

• Neurology
• Neuroscience
• Pharmacology

Background:

• Primary headaches, including migraine and cluster headache, are prevalent neurological disorders affecting a significant portion of the adult population.
• Headache pain is linked to intracranial blood vessels and neurotransmitter release, with calcitonin gene-related peptide (CGRP) specifically associated with primary headache pathophysiology.
• Current acute treatments like triptans alleviate headache and normalize CGRP levels, acting via vasoconstriction and presynaptic inhibition.

Purpose of the Study:

• To review the role of CGRP in human cranial circulation.
• To explore the potential of CGRP antagonists in treating primary headaches.
• To discuss the development and pharmacological profile of small-molecule CGRP antagonists.

Main Methods:

• Review of existing literature on CGRP in cranial circulation and its role in primary headaches.
• Analysis of the mechanism of action of triptans in relation to CGRP.
• Examination of the pharmacological data for novel small-molecule CGRP antagonists.

Main Results:

• CGRP is demonstrably linked to primary headache disorders, unlike other neuronal messengers.
• Triptan therapy effectively reduces headache and CGRP levels, with mechanisms involving vasoconstriction and nerve inhibition.
• New small-molecule CGRP antagonists exhibit high selectivity for CGRP receptors and show efficacy in acute migraine relief.

Conclusions:

• CGRP is a central player in the pathophysiology of migraine and cluster headaches.
• CGRP antagonists represent a promising therapeutic strategy for acute primary headache treatment, potentially offering improved cardiovascular safety profiles compared to triptans.
• The development of selective CGRP antagonists marks a significant advancement in headache pharmacotherapy.